ID
37843
Description
Study ID: 111634 Clinical Study ID: 111634 Study Title: A phase III, open, controlled study in South Africa to assess the immunogenicity, safety and reactogenicity of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine administered as a 3-dose (6, 10, 14 weeks) primary immunization course in HIV infected infants, HIV exposed uninfected infants and HIV unexposed uninfected infants followed by a booster vaccination at 9-10 months of age. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00829010 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Pneumococcal vaccine GSK1024850A Trade Name: Tritanrix-HepB/Hib, Rotarix Study Indication: Infections, Streptococcal This phase III trial studies the immunogenicity, safety and reactogenicity of a 10-valent pneumococcal conjugate vaccine in three groups of infants that differ by HIV status: HIV-positive infants, HIV-negative infants who are exposed to the virus (by their HIV-positive mother), and HIV-negative infants who are not exposed. The study consists of Screening at 4-8 weeks of age (only for HIV-positive and HIV-exposed infants without HIV-DNA test) and 10 subsequent Visits over a period of 23 months. There are five study cohorts: HIV-positive and HIV-exposed participants receive the vaccine at Visits 1, 2, 3 (i.e. 6, 10 and 14 weeks of life; primary course) and 5 (9-10 months of age; booster), whereas HIV-negative, unexposed infants are randomly assigned to one of three vaccination schedules: the aforementioned schedule consisting of the primary course and the booster, or the 3-dose primary course only without the booster vaccination, or a different primary course consisting of only two vaccinations at Visits 1 and 3 (6 and 14 weeks of age) followed by a booster at Visit 5 (9-10 months). Visit 1 is scheduled at 6-10 weeks of life. The interval between Visits 1 and 2, 2 and 3, as well as 3 and 4 has to be 28-42 days each. Visit 5 then takes place at 9-10 months of age. The interval between Visit 5 and 6 again has to be 28-42 days. Visit 7 is scheduled at 12-13 months of age, Visit 8 at 15-18 months, Visit 9 at 16-19 months, and the final Visit 10 is performed when the subjects are 24-27 months old. This form contains the study's Inclusion/Exclusion Criteria and is to be filled in at Visit 1.
Keywords
Versions (1)
- 8/27/19 8/27/19 -
Copyright Holder
GlaxoSmithKline
Uploaded on
August 27, 2019
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
10-valent pneumococcal vaccine in HIV-positive, HIV-exposed and HIV-negative infants - NCT00829010
Eligibility Criteria
- StudyEvent: ODM
Description
Eligibility check
Alias
- UMLS CUI-1
- C1516637
Description
If No, fill in all items below corresponding to violations of any inclusion/exclusion criteria. Do not enter the subject into the study if he/she failed any inclusion or exclusion criteria below.
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1516637
- UMLS CUI [1,2]
- C1550543
Description
Inclusion Criteria
Alias
- UMLS CUI-1
- C1512693
Description
Gender and age at first vaccination
Data type
boolean
Alias
- UMLS CUI [1]
- C0079399
- UMLS CUI [2,1]
- C0001779
- UMLS CUI [2,2]
- C0205435
- UMLS CUI [2,3]
- C0042196
Description
Parents/guardians protocol compliance
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0525058
- UMLS CUI [1,2]
- C0030551
- UMLS CUI [2,1]
- C0525058
- UMLS CUI [2,2]
- C1274041
Description
informed consent obtained from the parent(s)/guardian(s)
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0021430
- UMLS CUI [1,2]
- C0030551
- UMLS CUI [2,1]
- C0021430
- UMLS CUI [2,2]
- C1274041
Description
No known/suspected health problems contraindicating immunizations, by medical history and examination
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0332296
- UMLS CUI [1,2]
- C0750491
- UMLS CUI [1,3]
- C1446390
- UMLS CUI [1,4]
- C1301624
- UMLS CUI [1,5]
- C0020971
- UMLS CUI [2,1]
- C0332296
- UMLS CUI [2,2]
- C0205309
- UMLS CUI [2,3]
- C1446390
- UMLS CUI [2,4]
- C1301624
- UMLS CUI [2,5]
- C0020971
- UMLS CUI [3]
- C0262926
- UMLS CUI [4]
- C0031809
Description
Exclusion Criteria
Alias
- UMLS CUI-1
- C0680251
Description
Recent or planned use of any other investigational or non-registered product
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1524063
- UMLS CUI [1,2]
- C0013230
- UMLS CUI [1,3]
- C0347984
- UMLS CUI [1,4]
- C2347804
- UMLS CUI [2,1]
- C1524063
- UMLS CUI [2,2]
- C0013230
- UMLS CUI [2,3]
- C0332185
Description
family history of hereditary immunodeficiency other than HIV infection
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0241889
- UMLS CUI [1,2]
- C0439660
- UMLS CUI [1,3]
- C0021051
- UMLS CUI [1,4]
- C1705847
- UMLS CUI [1,5]
- C0019693
Description
Applicable only for subjects who have been enrolled using the initial ICF
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0000768
- UMLS CUI [1,2]
- C0205164
- UMLS CUI [2,1]
- C0008679
- UMLS CUI [2,2]
- C0205404
- UMLS CUI [2,3]
- C1705847
- UMLS CUI [2,4]
- C0019693
Description
For HIV infected infants
Data type
boolean
Alias
- UMLS CUI [1]
- C1976611
Description
Administration of immunoglobulins and/or blood products, since birth or planned during study
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1533734
- UMLS CUI [1,2]
- C0021027
- UMLS CUI [1,3]
- C0262926
- UMLS CUI [2,1]
- C1533734
- UMLS CUI [2,2]
- C0021027
- UMLS CUI [2,3]
- C1301732
- UMLS CUI [2,4]
- C0347984
- UMLS CUI [2,5]
- C2347804
- UMLS CUI [3,1]
- C0371802
- UMLS CUI [3,2]
- C0262926
- UMLS CUI [4,1]
- C0371802
- UMLS CUI [4,2]
- C1301732
- UMLS CUI [4,3]
- C0347984
- UMLS CUI [4,4]
- C2347804
Description
The exclusion criteria concerning the previous vaccination against rotavirus is applicable only for subjects who have been enrolled during the Amendment 1/ Amendment 2 ICF
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0205156
- UMLS CUI [1,2]
- C0042196
- UMLS CUI [1,3]
- C0012546
- UMLS CUI [2,1]
- C0205156
- UMLS CUI [2,2]
- C0042196
- UMLS CUI [2,3]
- C0039614
- UMLS CUI [3,1]
- C0205156
- UMLS CUI [3,2]
- C0042196
- UMLS CUI [3,3]
- C0043167
- UMLS CUI [4,1]
- C0205156
- UMLS CUI [4,2]
- C0042196
- UMLS CUI [4,3]
- C0121772
- UMLS CUI [5,1]
- C0205156
- UMLS CUI [5,2]
- C0042196
- UMLS CUI [5,3]
- C0038410
- UMLS CUI [6,1]
- C0205156
- UMLS CUI [6,2]
- C0042196
- UMLS CUI [6,3]
- C0597418
Description
History of, or intercurrent, diphtheria, tetanus, pertussis, and Haemophilus influenzae type b disease
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0262926
- UMLS CUI [1,2]
- C0012546
- UMLS CUI [2,1]
- C0277557
- UMLS CUI [2,2]
- C0012546
- UMLS CUI [3,1]
- C0262926
- UMLS CUI [3,2]
- C0039614
- UMLS CUI [4,1]
- C0277557
- UMLS CUI [4,2]
- C0039614
- UMLS CUI [5,1]
- C0262926
- UMLS CUI [5,2]
- C0043167
- UMLS CUI [6,1]
- C0277557
- UMLS CUI [6,2]
- C0043167
- UMLS CUI [7,1]
- C0262926
- UMLS CUI [7,2]
- C0121772
- UMLS CUI [8,1]
- C0277557
- UMLS CUI [8,2]
- C0121772
Description
allergic disease or reactions likely to be exacerbated by any component of the vaccines
Data type
boolean
Alias
- UMLS CUI [1,1]
- C2106654
- UMLS CUI [1,2]
- C0750492
- UMLS CUI [1,3]
- C4086268
- UMLS CUI [1,4]
- C1705248
- UMLS CUI [1,5]
- C0042210
Description
Applicable only for subjects who have been enrolled using the initial ICF
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0262926
- UMLS CUI [1,2]
- C0027765
- UMLS CUI [2,1]
- C0262926
- UMLS CUI [2,2]
- C0036572
Description
Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea or mild upper respiratory infection, provided the body temperature is <38°C (rectal measurement) or <37.5°C (for oral/axi llary/tympanic measurements). Study entry should be delayed until the illness has improved.
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0001314
- UMLS CUI [1,2]
- C0521116
Description
From approval of protocol amendment II, the exclusion criterion will be modified as follow: Babies whose weight for age is < 3rd percentile at Visit 1, using standard growth charts, with the exception of HIV infected infants for which the decision of enrolment is left to the investigator’s discretion. (Amended 29 June 2009)
Data type
boolean
Alias
- UMLS CUI [1]
- C0517416
Description
warrants deferral of the vaccination Applicable only for subjects who have been enrolled using the Amendment 1 / Amendment2 ICF
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0017160
- UMLS CUI [1,2]
- C0332185
Description
Applicable only for subjects who have been enrolled using the Amendment 1 / Amendment2 ICF
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0750502
- UMLS CUI [1,2]
- C0262926
- UMLS CUI [1,3]
- C0017178
- UMLS CUI [1,4]
- C0008679
- UMLS CUI [2,1]
- C0017189
- UMLS CUI [2,2]
- C0000768
- UMLS CUI [2,3]
- C4072785
- UMLS CUI [3]
- C0021933
- UMLS CUI [4,1]
- C0205394
- UMLS CUI [4,2]
- C0009488
- UMLS CUI [4,3]
- C0205082
- UMLS CUI [4,4]
- C0008961
- UMLS CUI [4,5]
- C0022423
Similar models
Eligibility Criteria
- StudyEvent: ODM
C1550543 (UMLS CUI [1,2])
C0001779 (UMLS CUI [2,1])
C0205435 (UMLS CUI [2,2])
C0042196 (UMLS CUI [2,3])
C0030551 (UMLS CUI [1,2])
C0525058 (UMLS CUI [2,1])
C1274041 (UMLS CUI [2,2])
C0030551 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2,1])
C1274041 (UMLS CUI [2,2])
C0750491 (UMLS CUI [1,2])
C1446390 (UMLS CUI [1,3])
C1301624 (UMLS CUI [1,4])
C0020971 (UMLS CUI [1,5])
C0332296 (UMLS CUI [2,1])
C0205309 (UMLS CUI [2,2])
C1446390 (UMLS CUI [2,3])
C1301624 (UMLS CUI [2,4])
C0020971 (UMLS CUI [2,5])
C0262926 (UMLS CUI [3])
C0031809 (UMLS CUI [4])
C0013230 (UMLS CUI [1,2])
C0347984 (UMLS CUI [1,3])
C2347804 (UMLS CUI [1,4])
C1524063 (UMLS CUI [2,1])
C0013230 (UMLS CUI [2,2])
C0332185 (UMLS CUI [2,3])
C0439660 (UMLS CUI [1,2])
C0021051 (UMLS CUI [1,3])
C1705847 (UMLS CUI [1,4])
C0019693 (UMLS CUI [1,5])
C0205164 (UMLS CUI [1,2])
C0008679 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C1705847 (UMLS CUI [2,3])
C0019693 (UMLS CUI [2,4])
C0021027 (UMLS CUI [1,2])
C0262926 (UMLS CUI [1,3])
C1533734 (UMLS CUI [2,1])
C0021027 (UMLS CUI [2,2])
C1301732 (UMLS CUI [2,3])
C0347984 (UMLS CUI [2,4])
C2347804 (UMLS CUI [2,5])
C0371802 (UMLS CUI [3,1])
C0262926 (UMLS CUI [3,2])
C0371802 (UMLS CUI [4,1])
C1301732 (UMLS CUI [4,2])
C0347984 (UMLS CUI [4,3])
C2347804 (UMLS CUI [4,4])
C0042196 (UMLS CUI [1,2])
C0012546 (UMLS CUI [1,3])
C0205156 (UMLS CUI [2,1])
C0042196 (UMLS CUI [2,2])
C0039614 (UMLS CUI [2,3])
C0205156 (UMLS CUI [3,1])
C0042196 (UMLS CUI [3,2])
C0043167 (UMLS CUI [3,3])
C0205156 (UMLS CUI [4,1])
C0042196 (UMLS CUI [4,2])
C0121772 (UMLS CUI [4,3])
C0205156 (UMLS CUI [5,1])
C0042196 (UMLS CUI [5,2])
C0038410 (UMLS CUI [5,3])
C0205156 (UMLS CUI [6,1])
C0042196 (UMLS CUI [6,2])
C0597418 (UMLS CUI [6,3])
C0012546 (UMLS CUI [1,2])
C0277557 (UMLS CUI [2,1])
C0012546 (UMLS CUI [2,2])
C0262926 (UMLS CUI [3,1])
C0039614 (UMLS CUI [3,2])
C0277557 (UMLS CUI [4,1])
C0039614 (UMLS CUI [4,2])
C0262926 (UMLS CUI [5,1])
C0043167 (UMLS CUI [5,2])
C0277557 (UMLS CUI [6,1])
C0043167 (UMLS CUI [6,2])
C0262926 (UMLS CUI [7,1])
C0121772 (UMLS CUI [7,2])
C0277557 (UMLS CUI [8,1])
C0121772 (UMLS CUI [8,2])
C0750492 (UMLS CUI [1,2])
C4086268 (UMLS CUI [1,3])
C1705248 (UMLS CUI [1,4])
C0042210 (UMLS CUI [1,5])
C0027765 (UMLS CUI [1,2])
C0262926 (UMLS CUI [2,1])
C0036572 (UMLS CUI [2,2])
C0521116 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0262926 (UMLS CUI [1,2])
C0017178 (UMLS CUI [1,3])
C0008679 (UMLS CUI [1,4])
C0017189 (UMLS CUI [2,1])
C0000768 (UMLS CUI [2,2])
C4072785 (UMLS CUI [2,3])
C0021933 (UMLS CUI [3])
C0205394 (UMLS CUI [4,1])
C0009488 (UMLS CUI [4,2])
C0205082 (UMLS CUI [4,3])
C0008961 (UMLS CUI [4,4])
C0022423 (UMLS CUI [4,5])
No comments